WO2000060073A1 - Gene de polypeptide irg27, anticorps contre ce polypeptide et son utilisation therapeutique - Google Patents

Gene de polypeptide irg27, anticorps contre ce polypeptide et son utilisation therapeutique Download PDF

Info

Publication number
WO2000060073A1
WO2000060073A1 PCT/JP2000/001796 JP0001796W WO0060073A1 WO 2000060073 A1 WO2000060073 A1 WO 2000060073A1 JP 0001796 W JP0001796 W JP 0001796W WO 0060073 A1 WO0060073 A1 WO 0060073A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
gene
seq
sequence
irg27
Prior art date
Application number
PCT/JP2000/001796
Other languages
English (en)
Japanese (ja)
Inventor
Takashi Enjoji
Naoki Tohdoh
Original Assignee
Sumitomo Pharmaceuticals Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharmaceuticals Co., Ltd. filed Critical Sumitomo Pharmaceuticals Co., Ltd.
Publication of WO2000060073A1 publication Critical patent/WO2000060073A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes

Abstract

L'invention concerne de nouveaux diagnostics du cancer, une méthode diagnostique, etc., par utilisation d'un gène codant pour un polypeptide dénommé IRG27 dont l'expression est induite par l'inactivation de p53 et est élevée dans plusieurs cancers se manifestant chez l'homme, tels que le cancer de l'oesophage, le cancer de l'estomac, le cancer du poumon, le cancer du rein, le cancer de la thyroïde, le cancer de la parotide, le cancer de l'uretère, le cancer de la vésicule, le cancer de l'utérus, le cancer du foie, le cancer du sein, le cancer de l'ovaire et le cancer des trompes. L'invention concerne également un anticorps contre IRG27.
PCT/JP2000/001796 1999-03-31 2000-03-23 Gene de polypeptide irg27, anticorps contre ce polypeptide et son utilisation therapeutique WO2000060073A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP11/93641 1999-03-31
JP9364199 1999-03-31

Publications (1)

Publication Number Publication Date
WO2000060073A1 true WO2000060073A1 (fr) 2000-10-12

Family

ID=14087999

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2000/001796 WO2000060073A1 (fr) 1999-03-31 2000-03-23 Gene de polypeptide irg27, anticorps contre ce polypeptide et son utilisation therapeutique

Country Status (1)

Country Link
WO (1) WO2000060073A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001087349A1 (fr) * 2000-05-19 2001-11-22 Sumitomo Pharmaceuticals Company, Limited Agents carcinostatiques ou agents antiviraux contenant une proteine ou un gene irg27
WO2003023031A1 (fr) * 2001-09-04 2003-03-20 Nippon Shinyaku Co., Ltd. Methode d'evaluation de l'efficacite d'une therapie aux acides nucleiques
WO2005093063A1 (fr) * 2004-03-29 2005-10-06 Medical & Biological Laboratories Co., Ltd. Kit pour diagnostic de cancer consistant et medicament pour therapie contre un cancer consistant
EP2169060A1 (fr) 2004-06-02 2010-03-31 alphaGEN Co., Ltd. Nouveau polypeptide utile pour diagnostiquer et pour traiter le cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BRIAN T. PENTECOST: "Expression and estrogen regulation of the HEM45 mRNA in human tumor lines and in the rat uterus", J. STEROID BIOCHEM. MOLEC. BIOL., vol. 64, no. 1/2, 1998, pages 25 - 33, XP002928832 *
CELINE GONGORA ET. AL.: "Molecular cloning of a new interferon-induced PML. nuclear body-associated protein", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 31, 1997, pages 19457 - 19463, XP002928833 *
DATABASE BIOSIS GUSTAFSSON BRITT ET AL: "Overexpression of MDM2 in Acute Childhood Lymphoblastic Leukemia" *
PEDIATRIC HEMATOLOGY AND ONCOLOGY, vol. 15, no. 6, 1998, pages 519 - 526 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001087349A1 (fr) * 2000-05-19 2001-11-22 Sumitomo Pharmaceuticals Company, Limited Agents carcinostatiques ou agents antiviraux contenant une proteine ou un gene irg27
WO2003023031A1 (fr) * 2001-09-04 2003-03-20 Nippon Shinyaku Co., Ltd. Methode d'evaluation de l'efficacite d'une therapie aux acides nucleiques
WO2005093063A1 (fr) * 2004-03-29 2005-10-06 Medical & Biological Laboratories Co., Ltd. Kit pour diagnostic de cancer consistant et medicament pour therapie contre un cancer consistant
EP2169060A1 (fr) 2004-06-02 2010-03-31 alphaGEN Co., Ltd. Nouveau polypeptide utile pour diagnostiquer et pour traiter le cancer
US8222393B2 (en) 2004-06-02 2012-07-17 Tss Biotech Inc. Polypeptide useful for cancer diagnosis and treatment

Similar Documents

Publication Publication Date Title
KR101828290B1 (ko) 자궁내막암 마커
US7557204B2 (en) CUDR as biomarker for cancer progression and therapeutic response
JP4614472B2 (ja) 乳房の疾患の検出に有用な試薬および方法
WO2003026493A2 (fr) Diagnostic et traitement de maladies induites par des mutations dans le gene cd72
CA2676179C (fr) Variantes d'epissages specifiques metastatiques de mena, et utilisation de celles-ci dans le diagnostic, le pronostic et le traitement de tumeurs
JPH11507212A (ja) Ｄｎａ配列及びエンコードされた乳房に特異的な乳癌たんぱく質
WO2007026895A1 (fr) Kit et procédé pour détecter le cancer urothélial
WO1998015657A1 (fr) Reactifs et procedes utiles pour detecter des maladies de la prostate
JP2001523472A (ja) 乳房の疾患の検出に有用な試薬および方法
JP2001521744A (ja) 乳房の疾患の検出に有用な試薬および方法
JP7150018B2 (ja) 新規なｃｉｐ２ａバリアント及びその使用
WO2000060073A1 (fr) Gene de polypeptide irg27, anticorps contre ce polypeptide et son utilisation therapeutique
US20100330554A1 (en) Diagnostic kit for solid cancer and medicament for solid cancer therapy
JP4576168B2 (ja) 膀胱尿管逆流症または間質性膀胱炎の検査方法
US20100285452A1 (en) Molecular Markers for the Diagnosis and Treatment of Tumors
WO2006013474A2 (fr) Udp-n-acetyl-d-galactosamine: polypeptide n-acetylgalactosaminyltransferase 6 (ppgainac-t6) arnm ou un peptide utilise en tant que nouveau marqueur pour la detection de cellules cancereuses
JP4473870B2 (ja) 新規キメラ蛋白質およびそれをコードする遺伝子、並びに、これらの遺伝子と蛋白質を用いた白血病の判別手段
KR101093508B1 (ko) 대장암 진단용 조성물 및 그 용도
JPWO2004061103A1 (ja) 新規タンパク質及びそれをコードする遺伝子
US7928188B2 (en) Antigen polypeptide for the diagnosis and/or treatment of ovarian cancer
JP5354484B2 (ja) がん検出方法
WO2005118811A1 (fr) Nouveau polypeptide utile pour diagnostiquer et pour traiter le cancer
JP2010284135A (ja) 新規遺伝子ファミリーｅｃｓａ
KR20110036558A (ko) 대장암 진단용 조성물 및 그 용도
KR20110036556A (ko) 대장암 진단용 조성물 및 그 용도

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 609565

Kind code of ref document: A

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase